Botox, sacral nerve stimulation highlighted as emerging OAB treatments for elderly patients
September 15th 2022Two studies shared at the 2022 Annual Meeting of the South Central Section of the AUA highlighted onabotulinumtoxinA and sacral nerve stimulation as alternative treatment options for patients older than 70 years with overactive bladder.
Stereotactic ablative radiation effective in systemic therapy–naïve oligometastatic kidney cancer
August 23rd 2022“There has never been a clinical trial for these patients. It is unclear whether these patients should be treated with medication, surgery, or another approach. This represents an unmet medical need,” said Raquibul Hannan, MD, PhD.
FDA grants priority review to olaparib/abiraterone combo for mCRPC
August 16th 2022The application is supported by the phase 3 PROpel trial, which showed that adding olaparib to frontline abiraterone acetate and prednisone/prednisolone significantly improved radiographic progression-free survival in patients with mCRPC.
Reader reproducibility high with 18F-rhPSMA-7.3 image interpretation in prostate cancer
June 15th 2022“These findings from the SPOTLIGHT study showed high inter-reader and intra-reader agreement for interpretation of 18F-rhPSMA-7.3 PET/CT scans in the setting of biochemical recurrence,” said Phillip Kuo, MD, PhD.
PSA response linked to improved survival with darolutamide triplet in mHSPC
June 8th 2022Overall survival was higher among patients with mHSPC who achieved undetectable PSA levels when treated with the triplet of darolutamide, ADT, and docetaxel, according to an analysis from the phase 3 ARASENS trial.